Evidence map›Paper›PMID 40341104›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2025

Doubling of triazole resistance rates in invasive aspergillosis over a 10-year period, Belgium, 1 April 2022 to 31 March 2023.

Lize Cuypers, Robina Aerts, Otto Van de Gaer, Lore Vinken, Rita Merckx, Veerle Gerils, Greetje Vande Velde, Agustin Reséndiz-Sharpe, Johan Maertens, Katrien Lagrou

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Characteristics of individualAntimicrobial agents and chemotherapy · 2026
    Article
  3. Article
  4. Article
  5. Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lize CuypersDepartment of Laboratory Medicine, National Reference Centre for Mycosis, University Hospitals Leuven, Leuven, Belgium.
Robina AertsDepartment of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, KU Leuven, Leuven, Belgium.
Otto Van de GaerDepartment of Laboratory Medicine, National Reference Centre for Mycosis, University Hospitals Leuven, Leuven, Belgium.
Lore VinkenDepartment of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, KU Leuven, Leuven, Belgium.
Rita MerckxDepartment of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, KU Leuven, Leuven, Belgium.
Veerle GerilsDepartment of Laboratory Medicine, National Reference Centre for Mycosis, University Hospitals Leuven, Leuven, Belgium.
Greetje Vande VeldeDepartment of Imaging and Pathology, Biomedical MRI unit, KU Leuven, Leuven, Belgium.
Agustin Reséndiz-SharpeDepartment of Imaging and Pathology, Biomedical MRI unit, KU Leuven, Leuven, Belgium.
Johan MaertensDepartment of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, KU Leuven, Leuven, Belgium.
Katrien LagrouDepartment of Laboratory Medicine, National Reference Centre for Mycosis, University Hospitals Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundDutch national treatment guidelines for fungal infections have been adapted based on surveillance findings of triazole resistance rates >10% in

Indexed as

Antifungal AgentsAspergillosisAspergillusAspergillus fumigatusDrug Resistance, FungalTriazolesAdolescentAdultAgedAged, 80 and overBelgiumChildChild, PreschoolFemaleHumansInfantAntifungal AgentsTriazolesAspergillus fumigatusBelgiumCYP51A sequencingempirical antifungal treatmentnational prospective surveillancetriazole resistance

Identifiers

PMID40341104
PMCPMC12066980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.